Abeona Therapeutics Inc. (ABEO) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $5.83, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $18.86 vs price $5.84 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $342M below $400M minimum.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic... Read more
Hold if already holding. Not a fresh buy at $5.83, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $18.86 vs price $5.84 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $342M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $342M below $400M minimum. Not in investable universe. Score 4.2/10, moderate confidence.
Passes 5/8 gates (no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: speculative.
Recent developments
updated 2026-08-17Recent Developments — Abeona Therapeutics Inc.
Latest news
- NEWS Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21 — benzinga Aug 14, 2026
- NEWS Abeona Therapeutics Q2 2026 Earnings Call Transcript — benzinga Aug 13, 2026
- NEWS 12 Health Care Stocks Moving In Thursday's Pre-Market Session — benzinga Aug 13, 2026
Generated 2026-08-17T15:02:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $5.83, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $18.86 vs price $5.84 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $342M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $342M below $400M minimum. Not in investable universe. Target $7.50 (+28.6%), stop $5.53 (−5.4%), A.R:R 0.0:1. Score 4.2/10, moderate confidence.
Take-profit target: $7.50 (+28.4% upside). Target $7.50 (+28.6%), stop $5.53 (−5.4%), A.R:R 0.0:1. Stop-loss: $5.53.
DATA_ISSUE: analyst_target_implausible (raw $18.86 vs price $5.84 — ratio 3.2×). Rejected, falling back to technical TP.; Market cap $342M below $400M minimum.
Abeona Therapeutics Inc. trades at a P/E of N/A (forward -32.6). TrendMatrix value score: 1.1/10. Verdict: Hold.
12 analysts cover ABEO with a consensus score of 4.3/5. Average price target: $19.
What does Abeona Therapeutics Inc. do?Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for...
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.